Einfluß des HMG- Co A- Reduktase- Hemmers Pravastatin in Kombination mit TACE auf das Langzeitüberleben bei Patienten mit hepatozellulärem Karzinom [thesis]

Hannah Graf
Tag der mündlichen Prüfung: 16.12.2010 FÜR PROF. DIETER JÜNGST Belghiti J et al. (1991): Intrahepatic recurrence after resection of hepatocellular carcinoma complicating cirrhosis. Ann Surg 214: 114-117 Bellosta S, Paoletti R, Corsini A (2004): Safety of Statins: Focus on Clinical Pharmacokinetics and Drug Interactions. Circulation 109: (Suppl III) 50-57 Bismuth H, Fecteau A (1998): Kombinationstherapie in der Onkologie-das hepatocelluläre Karzinom. Chirurg 69: 360-369 Blais L, Desgagne, A,
more » ... L, Desgagne, A, LeLorier J (2000): 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study. Arch Intern Med. 160: 2363-2368 Bloomston M, Binitie O, Fraji E, Murr M et al. (2002): Transcatheter arterial chemoembolization with or without radiofrequency ablation in the management of patients with advanced hepatic malignancy. Am Surg 68: 827-831 Bosch FX, Ribes J, Diaz M et al. (2004): Primary liver cancer: worlwide incidence and trends. Gastroenterology 127: 5-16 Boudreau DM, Gardner JS, Malone KE et al. (2004): The associaton between 3hydroxy-3-methylglutaryl coenzyme A inhibitor use and breast carcinoma risk among postmenopausal women: a case-control-study. Cancer 100: 2308-2316 Bruix J, LLovet JM, Castells A et al. (1998): Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized controlled trial in a single institution. Hepatology 27: 1578-1583 Bruix J, Sherman M, Llovet JM et al. (2001): Clinical managment of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatology 35: 421-430 Bruix J, Sherman M (2005): Practice Guidelines Committee, American association for the Study of Liver Diseases: Management of hepatocellular carcinoma. Hepatology 42: 1208-1236 Burrel M, Llovet JM, Ayuso C et al. (2003): MRI Angiography is superior to helical CT for detection of HCC PRIOR TI Liver transplantation: an explant correlation. Hepatology 38: 1034-1042 chondrial pathway of apoptosis in human lymphoblasts and myeloma cells. Carcinogenesis 26: 883-891 Camma C, Schepis F, Orlando A et al. (2002): Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: Meta-Analysis of Randomized Controlled Trials. Radiology 224: 47-54 Cauley JA, Zmuda JM, Lul LY et al. (2003): Lipid lowering drug use and breast cancer in older women : a prospective study. J Womens Health 12: 749-756 Chan AO, Yuen MF, Hui CK et al. (2003): A prospective study regarding the complications of transcatheter intraarterial lipiodol chemoembolization in patients with hepatocellular carcinoma. Cancer 94: 1747-1752 Chen CJ, Yu MW, Liaw YF (1997): Epidemiological characteristics and risk factors of hepatocellular carcinoma. Journal Gastroenterol Hepatol 12: S294-308 Cheng BQ, Jia CQ, Liu CT et al. (2008): Chemoembolization combined with radiofrequency ablation for patients with hepatocellular carcinoma larger than 3cm: a randomized controlled trial. JAMA 299 (14): 1669-1677 Cheng HY, Shou Y, Wang X et al. (2004): Adjustment of lipiodol dose according to tumor blood supply during transcatheter arterial chemoembolization for large hepatocellular carcinoma by multidetector helical CT. World J Gastroenterol 10: 2753-2755 Chen MS, Li QJ, Zheng J et al. (2006): A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg 243: 321-328 Chow PK, Tai BC, Tan CK, et al. (2002): High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: a multicenter randomized controlled trial. Hepatology 36: 1221-1226 CLIP Investigators (The cancer of the Liver Italian Program) (2000): Prospective validation of the CLIP Score: a new prognostic system for patients with cirrhosis and hepatcelullar carcinoma. Hepatology 31: 840-845 Cohen DE, Anania FA, Chalasani N (2006): An assessment of statin safety by hepatologists. Am J Cardiol 97: S77-S81 Coleman WB (2003): Mechanism of human hepatocarcinogenesis. Curr Mol Med 3: 573-588 Colli A, Franquelli M, Casazza G et al. (2006): Accuracy of ultrasonography, spiral ct, magnetic resonance and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review. Am J Gastroenterology 101: 513-523 Collier J, Sherman M (1998): Screening for hepatocellular carcinoma. Hepatology 27: 273-278 Collisson EA, Kleer C, Wu M et al. (2003): Atorvastatin prevents RhoC isoprenylation, invasion and metastasis in human melanoma cells. Mol Cancer Ther 2: 941-948 Coogan PF, Rosenberg L, palmer JR et al. (2002): Statin unse and the risk of breast and prostate cancer. Epidemiology 13: 262-267 Crisby M, Nordin-Frederiksson G, Shah PK, Yano J et al. (2001): Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases and cell death in human carotis plaques: implications for plaque stabilization. Circulation 103: 926-933 Curley SA, Izzo F, Gallipoli A et al. (1995): Identification and screening of 416 patients with chronic hepatitis at high risk to develop hepatocellular cancer. Ann Surg 222: 375-380 Demierre MF, Higgins P, Gruber S et al. (2005): Statins and cancer prevention. Nature 5: 930-942 Denoyelle C, Vasse M, Korner M et al. (2001): Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signalling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study. Carcinogenesis 22: 1139-1148 Di Bisceglie A (1997): Hepatitis C and hepatocellular carcinoma. Hepatology 26 [Suppl 1]: 34S-38S Dimitroulakos J, Thai S, Wasfy GH et al. (2000): Lovastatin induces a pronounced differentiation response in acute myeloid leukemia. Leuk Lymphoma 40: 167-178 Johnson PJ (2002): Hepatocellular carcinoma:is current therapy really altering outcome? Gut 51: 459-462 Jones DE, Metcalf JV, Collier JD, Bassendine MF, James OF (1997): Hepatocellular carcinoma in primary cirrhosis and its impact on outcomes. Hepatology 26: 1138-1142 Kaneko R, Tsuji N et al. (2007): Survivin down-regulation plays a crucial role in 3hydroxy-3-methylglutaryl coenzyme A reductase inhibitor-induced apoptosis in cancer. J Biol Chem 282(27): 19273-19281 Kassahun WT, Fangmann J, Harms J et al. (2006): Liver resection and transplantation in the managment of hepatocellular carcinoma: a review. Exp Clin Transplant 4: 549-558 Kath R, Höffken K (1998): Mechanismen der Metastasierung und deren Beeinflussung. Onkologe 4: 560-565 Katz MS, Minsky BD, Saltz LB et al. (2005): Association of statin use with a pathologic complete response to neoadjuvant chemoradiation for rectal cancer. Int J Radiat Oncol Biol Phys 62: 1363-1370 Kawata S, Kakimoto H, Ishiguro H et al. (1992): Effect of pravastatin, a potent 3hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, on survival of AH130 hepatoma-bearing rats. Jpn J Cancer Res 83(11): 1120-1123 Kawata S, Nagase T, Yamasaki E, Ishiguro H et al. (1994): Modulation of the mevalonate pathway and cell growth by pravastatin and d-limonene in a human hepatoma cell line (Hep G2). Br J Cancer 69: 1015-1020 Kawata S, Yamasaki E, Nagase T, Inui Y, Ito N et al. (2001): Effect of pravastatin on survival in patients with hepatocellular advanced hepatocellular carcinoma. A randomized controlled trial. Br J Cancer 84: 886-891 Kaye JA, Meier CR, Walker AM et al. (2002): Statin use, hyperlipidaemia and the risk of vreast cancer. Br J Cancer 86: 1436-1439 Khurana V, Kochhar R, Bejjanki H et al. (2005): Statins reduce the incidence of lung cancer: a study of half a million US veterans. J Clin Oncol 23: 1006 Kochhar R, Khurana V, Bejjanki H et al. (2005): Statins reduce breast cancer risk: a case-control-study in US female veterans. J Clin Oncology 23: 514
doi:10.5282/edoc.12544 fatcat:bbzzcxyh2neo5ety5snf6xf6gi